Laryngeal dyspnea in relation to an interaction between acenocoumarol and topical econazole lotion

American Journal Geriatric Pharmacotherapy

Volumn 6, Issue 3, 2008, Pages 173-177

  Wey, Pierre François ^a   Petitjeans, Fabrice ^a   Lions, Christophe ^a   Ould Ahmed, Mehdi ^a   Escarment, Jacques ^a  

^a HIA Desgenettes   (France)

Author keywords

acenocoumarol; econazole; laryngeal hematoma; upper airway obstruction

Indexed keywords

ACENOCOUMAROL; ACETYLSALICYLIC ACID; ECONAZOLE; FUROSEMIDE; IRBESARTAN; OXYGEN; PHYTOMENADIONE; PROTHROMBIN; PROTHROMBIN COMPLEX; THROMBOPLASTIN; URAPIDIL;

AGED; ARTICLE; BLOOD CLOTTING DISORDER; CASE REPORT; DEEP VEIN THROMBOSIS; DERMATITIS; DRUG POTENTIATION; DYSPNEA; EMERGENCY WARD; FACE MASK; FEMALE; HEART ATRIUM FIBRILLATION; HEMATOMA; HUMAN; HYPERTENSION; INTENSIVE CARE UNIT; INTERNATIONAL NORMALIZED RATIO; LABORATORY TEST; LARYNGOSCOPY; LARYNX DISORDER; LOTION; ORAL BLEEDING; PARTIAL THROMBOPLASTIN TIME; PATIENT TRANSPORT; PHYSICAL EXAMINATION; PRESCRIPTION; PRIORITY JOURNAL; PROTHROMBIN TIME; RECURRENT DISEASE; RESPIRATORY FAILURE; SPEECH DISORDER; TONSIL DISEASE; UPPER RESPIRATORY TRACT OBSTRUCTION;

ACENOCOUMAROL; ADMINISTRATION, TOPICAL; AGED, 80 AND OVER; ANTICOAGULANTS; ANTIFUNGAL AGENTS; ASPIRIN; BLOOD COAGULATION DISORDERS; DRUG INTERACTIONS; DYSPNEA; ECONAZOLE; FEMALE; HEMATOMA; HUMANS; LARYNGEAL DISEASES; LARYNGOSCOPY; PLATELET AGGREGATION INHIBITORS; PROTHROMBIN;

EID: 50449092697     PISSN: 15435946     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjopharm.2008.07.004     Document Type: Article

References (23)

1. Ufer M. Comparative pharmacokinetics of vitamin K antagonists: Warfarin, phenprocoumon and acenocoumarol. Clin Pharmacokinet 44 (2005) 1227-1246
2. Palareti G., Leali N., Coccheri S., et al. Bleeding complications of oral anticoagulant treatment: An inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet 348 (1996) 423-428
3. Verstuyft C., Robert A., Morin S., et al. Genetic and environmental risk factors for oral anticoagulant overdose. Eur J Clin Pharmacol 58 (2003) 739-745
4. Levine M.N., Raskob G., Beyth R.J., et al. Hemorrhagic complications of anticoagulant treatment: The Seventh ACCP Conference on Antithrombotic and Antithrombolytic Therapy. Chest 126 Suppl 3 (2004) 287S-310S
5. Freixa R., Blanch P., Ibernón M., et al. Identification of factors responsible for oral over-anticoagulation in outpatients with heart disease [in Spanish]. Rev Esp Cardiol 56 (2003) 65-72
6. Gonzàlez-Garcia R., Schoendorff G., Muñoz-Guerra M.F., et al. Upper airway obstruction by sublingual hematoma: A complication of anticoagulation therapy with aceno-coumarol. Am J Otolaryngol 27 (2006) 129-132
7. Ortln M., Olalla J.I., Muruzfibal M.J., et al. Miconazole oral gel enhances acenocoumarol anticoagulant activity: A report of three cases. Ann Pharmacother. 33 (1999) 175-177
8. Lang Jr. P.G., and Leclercq A.H. Increase in anticoagulant effect of warfarin in a patient using econazole cream. J Am Acad Dermatol 55 Suppl 5 (2006) S117-S119
9. Visser L.E., Penning-van Beest F.J., Kasbergen A.A., et al. Overanticoagulation associated with combined use of antifungal agents and coumarin anticoagulants. Clin Pharmacol Ther 71 (2002) 496-502
10. Lindquist M., and Edwards I.R. The WHO Programme for International Drug Monitoring, its database, and the technical support of the Uppsala Monitoring Center. J Rheumatol 28 (2001) 1180-1187
11. Naranjo C.A., Busto U., Sellers E.M., et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30 (1981) 239-245
12. Lira M., Chaudhari M., Devesa P.M., et al. Management of upper airway obstruction secondary to warfarin therapy: The conservative approach. J Laryngol Otol. 120 (2006) e12
13. Boster S.R., and Bergin J.J. Upper airway obstruction complicating warfarin therapy-with a note on reversal of warfarin toxicity. Ann Emerg Med 12 (1983) 711-715
14. Dentali F., Ageno W., and Crowther M. Treatment of coumarin-associated coagulopathy: A systematic review and proposed treatment algorithms. J Thromb Haemost. 4 (2006) 1853-1863
15. Lankiewicz M.W., Hays J., Friedman K.D., et al. Urgent reversal of warfarin with prothrombin complex concentrate. J Thromb Haemost 4 (2006) 967-970
16. Dentali F., and Ageno W. Management of coumarin-associated coagulopathy in the non-bleeding patient: A systematic review. Haematologica 89 (2004) 857-862
17. Ageno W., Crowther M., Steidl L., et al. Low dose oral vitamin K to reverse acenocoumarol-induced coagulopathy: A randomized controlled trial. Thromb Haemost 88 (2002) 48-51
18. Huttner H.B., Schellinger P.D., Hartmann M., et al. Hematoma growth and outcome in treated neurocritical care patients with intracerebral hemorrhage related to oral anticoagulant therapy: Comparison of acute treatment strategies using vitamin K, fresh frozen plasma, and prothrombin complex concentrates. Stroke 37 (2006) 1465-1470
19. Dager W.E., King J.H., Regalia R.C., et al. Reversal of elevated international normalized ratios and bleeding with low-dose recombinant activated factor VII in patients receiving warfarin. Pharmacotherapy 26 (2006) 1091-1098
20. Baillard C., Bianchi A., Gehan G., et al. Anaesthetic pre-operative assessment of chronic medications and herbal medicine use: A multicenter survey [in French]. Ann Fr Anesth Reanim 26 (2007) 132-135
21. Silingardi M., Ghirarduzzi A., Tincani E., et al. Miconazole oral gel potentiates warfarin anticoagulant activity. Thromb Haemost 83 (2000) 794-795
22. Singer M.I., Shapiro L.E., and Shear N.H. Cytochrome P-450 3A: Interactions with dermatologic therapies. J Am Acad Dermatol 37 (1997) 765-771
23. Thésaurus des Interactions Médicamenteuses. Saint- Denis, France: Agence Française de Sécurité Sanitaire des Produits de Santd (2008) 74